Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries. The health care giant said Friday that it will spend $335 in cash for each share of Shockwave. The total deal value includes cash acquired. The deal has already been approved by the boards of directors from both companies.
” He said he sees room for more growth both in and outside the United States, and the company expects annual sales to reach at least $1 billion. J&J will use cash on hand and debt to pay for the deal. Financing costs will dilute the company's adjusted earnings by 10 cents per share this year and 17 cents in 2025, Wolk said. The deal comes more than a year after J&J said it would spend $16 billion to buy another cardiovascular technology company, Abiomed.